Table 2.
Hazard Ratios for (1) Relapse, (2) Relapse and/or Contrast-Enhancing Lesions, and (3) Relapse With Disease-Modifying Treatment Switch as Adjunctive Censoring Parameter, With Extended Time Since Rituximab Infusion Compared With <8 Months
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.